Sadly for BAT, some may have quit smoking during Covid-19
As the pandemic spread, lockdowns meant BAT had to delay launches of vaping devices because the stores were shut
So, perhaps reassuringly, it turned out that tobacco wasn’t so defensive during this global health crisis after all.
After indications early in the pandemic that tobacco may hold up, on Tuesday, British American Tobacco (BAT) reduced its forecasts for full-year sales growth as Covid-19 lockdowns hurt business in emerging markets. The maker of Dunhill, Lucky Strike and Rothmans cigarettes depends on developing nations for one-quarter of its revenue.
SA has banned sales of tobacco products as part of a strict lockdown policy that BAT and other companies are fighting. Cigarette consumption has been disrupted by curfews in some markets, such as Bangladesh. In addition, smoking in markets such as Vietnam often takes place in bars and restaurants. With establishments closed, or consumers reluctant to venture out, there was less temptation to light up.
This slowdown provides good reason for pause for investors in BAT, led by the relatively new CEO Jack Bowles. With higher smoking rates, and the potential for consumers to trade up to more expensive brands as average incomes grow, these regions are supposed to offset the deterioration in developed markets as people there quit smoking. But now, because of the coronavirus hit, BAT expects a 7% decline in global industry sales volumes of cigarettes and heated-tobacco devices this year, more than the previously anticipated 5% fall.
This scenario has implications for competitors such as Philip Morris International and Japan Tobacco, which produces Winston and Benson & Hedges cigarettes. Japan Tobacco has been using its strong balance sheet to buy emerging-market brands over the past few years.
As the contagion spread and shined a spotlight on potential risks related to smoking, lockdowns meant BAT had to delay launches of new devices that heat rather than burn tobacco and e-cigarettes, because the stores where they’re sold were shut. The US market, the world’s biggest for e-cigarettes, was already struggling to recover after a spate of illnesses and deaths last year related to vaping.
Consequently, BAT expects to reach its target of annual sales of £5bn from tobacco alternatives a year later than planned, in 2025. The dislocation across cigarettes and newer products will lead to lower underlying earnings growth this year than previously forecast, as well as a slower reduction in debt.
However, it’s still too early to throw out the thesis that people will reach for cigarettes no matter what’s happening. In developed markets, consumption is holding up. In the US, for example, industry volumes could now fall by only about 4% this year, compared with the 5% previously anticipated, amid signs pointing to BAT gaining market share and few consumers switching to cheaper brands.
Vaping as a category is still reeling, but BAT is making headway with its Vuse and Vype brands. And it continues to invest in its tobacco heating device Glo, as well as in oral tobacco Velo. The strategy of having a balanced portfolio of new-generation products is wise. It’s not yet clear which of these categories will be the winner as traditional cigarette sales decline.
True, BAT had to lower its outlook and there is a risk that smokers will seek out cheaper brands in a recession, but at least the company is updating investors regularly. It also remains committed to its policy of paying out 65% of underlying earnings per share. Rival Imperial Brands cut its dividend last month.
BAT has not been immune from the pandemic, but the company is positioning itself well for the future. And who knows, its biotech subsidiary might even come up with a Covid-19 vaccine.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.